MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584318 | Name: Satranidazole

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Satranidazole is anti-bacterial used to treat periodontitis.

Chemical Structure

Satranidazole
Satranidazole
CAS#56302-13-7

Theoretical Analysis

MedKoo Cat#: 584318

Name: Satranidazole

CAS#: 56302-13-7

Chemical Formula: C8H11N5O5S

Exact Mass: 289.0481

Molecular Weight: 289.27

Elemental Analysis: C, 33.22; H, 3.83; N, 24.21; O, 27.65; S, 11.08

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Satranidazole; C 10213 Go; GO 10213
IUPAC/Chemical Name
1-(1-Methyl-5-nitro-1H-imidazol-2-yl)-3-(methylsulfonyl)-2-imidazolidinone
InChi Key
FNSHYEAUAUHIMB-UHFFFAOYSA-N
InChi Code
InChI=1S/C8H11N5O5S/c1-10-6(13(15)16)5-9-7(10)11-3-4-12(8(11)14)19(2,17)18/h5H,3-4H2,1-2H3
SMILES Code
O=C1N(S(=O)(C)=O)CCN1C2=NC=C([N+]([O-])=O)N2C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 289.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Rathi PB, Mourya VK. Solubility Prediction of Satranidazole in Aqueous N,N-dimethylformamide Mixtures Using Extended Hildebrand Solubility Approach. Indian J Pharm Sci. 2012 May;74(3):254-8. doi: 10.4103/0250-474X.106068. PubMed PMID: 23439726; PubMed Central PMCID: PMC3574536. 2: Ray DK, Shrivastava VB, Tendulkar JS, Dutta AK, Bhopale KK, Chatterjee DK, Nagarajan K. Comparative studies on the amoebicidal activity of known 5-nitroimidazole derivatives and CG 10213-Go in golden hamsters, Mesocricetus auratus, infected in the liver or caecum or both with trophozoites of Entamoeba histolytica. Ann Trop Med Parasitol. 1983 Jun;77(3):287-91. PubMed PMID: 6312905. 3: Rathi PB. Determination and evaluation of solubility parameter of satranidazole using dioxane-water system. Indian J Pharm Sci. 2010 Sep;72(5):671-4. doi: 10.4103/0250-474X.78546. PubMed PMID: 21695009; PubMed Central PMCID: PMC3116322. 4: Pradeep AR, Priyanka N, Kalra N, Naik SB. A randomized controlled clinical trial on the clinical and microbiological efficacy of systemic satranidazole in the treatment of chronic periodontitis. J Int Acad Periodontol. 2013 Apr;15(2):43-50. PubMed PMID: 23705535. 5: Nagarajan K, Gowrishankar R, Arya VP, George T, Nair MD, Shenoy SJ, Sudarsanam V. Nitroimidazoles, Part XXIII--activity of satranidazole series against anaerobic infections. Indian J Exp Biol. 1992 Mar;30(3):193-200. PubMed PMID: 1512026. 6: Zahoor A, Knight RC, Whitty P, Edwards DI. Satranidazole: mechanism of action on DNA and structure-activity correlations. J Antimicrob Chemother. 1986 Jul;18(1):17-25. PubMed PMID: 3531142. 7: Rathi PB. Solubility prediction of satranidazole in propylene glycol-water mixtures using extended hildebrand solubility approach. Indian J Pharm Sci. 2011 Nov;73(6):670-4. doi: 10.4103/0250-474X.100243. PubMed PMID: 23112403; PubMed Central PMCID: PMC3480754. 8: David J, Grewal RS, Kaul CL, Nargunde HS, Wagle GP, Ringe SY, Acharya TK. Pharmacological profile of 1-methylsulphonyl-3-(1-methyl-5-nitro-2-imidazolyl)-2-imidazolidinone (Go-10213), a new antiprotozoal agent, in comparison with metronidazole. Arzneimittelforschung. 1985;35(4):721-6. PubMed PMID: 4015738. 9: Ray DK, Tendulkar JS, Shrivastava VB, Nagarajan K. Comparative efficacy of metronidazole and another 5-nitroimidazole, CG-10213-Go, in caecal amoebiasis in albino mice (Mus musculus). J Antimicrob Chemother. 1982 Oct;10(4):355-7. PubMed PMID: 7142081. 10: Bansal K, Rawat MK, Jain A, Rajput A, Chaturvedi TP, Singh S. Development of satranidazole mucoadhesive gel for the treatment of periodontitis. AAPS PharmSciTech. 2009;10(3):716-23. doi: 10.1208/s12249-009-9260-z. Epub 2009 May 29. PubMed PMID: 19479385; PubMed Central PMCID: PMC2802163. 11: Chaudhari HS, Singh PP. Comparative drug susceptibility study of five clonal strains of Trichomonas vaginalis in vitro. Asian Pac J Trop Med. 2011 Jan;4(1):50-3. doi: 10.1016/S1995-7645(11)60031-X. Epub 2011 Jan 15. PubMed PMID: 21771415. 12: Ray DK, Chatterjee DK, Tendulkar JS. Comparative efficacy of Go 10213 and some nitroimidazoles against Trichomonas vaginalis and T. Foetus in mice infected subcutaneously. Ann Trop Med Parasitol. 1982 Apr;76(2):175-8. PubMed PMID: 6979983. 13: Hof H, Ströder J. Antibacterial activity of GO 10213, a nitroimidazole derivative. Antimicrob Agents Chemother. 1986 May;29(5):953-4. PubMed PMID: 3729357; PubMed Central PMCID: PMC284192. 14: Ray DK, Tendulkar JS, Shrivastava VB, Datta AK, Nagarajan K. A metronidazole-resistant strain of Trichomonas vaginalis and its sensitivity to Go 10213. J Antimicrob Chemother. 1984 Oct;14(4):423-6. PubMed PMID: 6334072. 15: Rao RR, Bhat N. Evaluation of the teratogenic potential in Ciba-Geigy Go 10213, a new nitroimidazole derivative: 1-methane-sulphonyl-3-(1-methyl-5-nitro-1H-imidazole-2-yl)-2- imidazolidinone, an amoebicide, trichomonicide and giardicide, in giardicide, in rats. Toxicology. 1983 Dec;29(1-2):157-61. PubMed PMID: 6658797. 16: Gowrishankar R, Phadke RP, Oza SD, Talwalker S. Satranidazole: experimental evaluation of activity against anaerobic bacteria in vitro and in animal models of anaerobic infection. J Antimicrob Chemother. 1985 Apr;15(4):463-70. PubMed PMID: 4008378. 17: Rathi PB, Mourya VK. Extended hildebrand solubility approach: satranidazole in mixtures of dioxane and water. Indian J Pharm Sci. 2011 May;73(3):315-9. doi: 10.4103/0250-474X.93518. PubMed PMID: 22457559; PubMed Central PMCID: PMC3309655. 18: Vaidya AB, Ray DK, Mankodi NA, Paul T, Sheth UK. Phase 1 tolerability and antiamoebic activity studies with 1-methylsulphonyl-3-(1-methyl-5-nitro-2-imidazolyl)-2-imidazolidinone (Go.10213): a new antiprotozoal agent. Br J Clin Pharmacol. 1983 Nov;16(5):517-22. PubMed PMID: 6639838; PubMed Central PMCID: PMC1428073. 19: Shashiprabha, Nayak SP, Rao KS, Nagarajan K, Shridhara K, Torreele E, Trunz BB. Nitroimidazooxazoles(#) Part xxiv, Search for Antileishmanial Agents: 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles as Potential Antileishmanial Agents. Indian J Pharm Sci. 2014 Jan;76(1):92-5. PubMed PMID: 24799745; PubMed Central PMCID: PMC4007262. 20: Priyanka N, Kalra N, Saquib S, Malgaonkar N, Tarakji B, Varsha J, Pradeep AR. Efficacy of Subgingivally Delivered Satranidazole in the Treatment of Type 2 Diabetes Subjects with Chronic Periodontitis: A Randomized Controlled Clinical Trial. J Int Acad Periodontol. 2015 Apr;17(2):42-8. Erratum in: J Int Acad Periodontol. 2015 Jul;17(3):81. Saquib, Shahabe [corrected to Saquib, Shahab]; Nikhil, Malgaonkar [corrected to Malgaonkar, Nikhil]; Tarakji, Bassel [added]. PubMed PMID: 26242010.